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788Background: ATX-101, an injectable form of deoxycholic acid, causes adipocytolysis when injected
subcutaneously into fat.Objective: We sought to evaluate the efficacy and safety of ATX-101.Methods: In this phase III trial (REFINE-2), adults dissatisfied with their moderate or severe submental fat
(SMF) were randomized to ATX-101 or placebo. Coprimary end points, evaluated at 12 weeks after last
treatment, were composite improvements of 1 or more grades and 2 or more grades in SMF observed on
both the validated Clinician- and Patient-Reported SMF Rating Scales. Other end points included magnetic
resonance imagingebased assessment of submental volume, assessment of psychological impact of SMF,
and additional patient-reported outcomes.Results: Among those treated with ATX-101 or placebo (n = 258/treatment group), 66.5% versus 22.2%,
respectively, achieved a composite improvement of 1 or more grades (Mantel-Haenszel risk ratio 2.98; 95%
confidence interval 2.31-3.85) and 18.6% versus 3.0% achieved a composite improvement of 2 or more
grades in SMF (Mantel-Haenszel risk ratio 6.27; 95% confidence interval 2.91-13.52; P\ .001 for both).
Those treated with ATX-101 were more likely to achieve submental volume reduction confirmed by
magnetic resonance imaging, greater reduction in psychological impact of SMF, and satisfaction with
treatment (P \ .001 for all). Overall, 85.7% of adverse events in the ATX-101 group and 76.9% in the
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d Standard treatment for submental
contouring has included aesthetic
surgical procedures and liposuction.
d This study used investigator and patient
assessment and magnetic resonance
imaging to demonstrate the efficacy of
ATX-101, an injectable form of
deoxycholic acid, for submental fat
reduction.
d ATX-101 may be an effective, nonsurgical
treatment for submental fat reduction.Submental fat (SMF) can
contribute to an unappealing
fullness under the chin,
negatively impacting facial
appearance and psycholo-
gical well-being.1 Aesthetic
surgical procedures and lipo-
suction have been the
standard treatment for SMF
reduction.2-4 However, ATX-
101 (Kybella in the United
States and Belkyra in Canada;
Kythera Biopharmaceuticals,
Inc, Westlake Village, CA
[an affiliate of Allergan plc,
Dublin, Ireland]), an inject-
able form of deoxycholic
acid, was recently approved for reduction of SMF.5
When injected subcutaneously into fat, ATX-101
causes adipocytolysis, which stimulates a local tissue
response consisting of macrophage infiltration
(to remove cellular debris and liberated lipids),
fibroblast recruitment, and collagen production
(neocollagenesis).6 The efficacy and safety of
ATX-101 have been extensively evaluated.7-12 In
this article, results from the phase III REFINE-2 trial,
which supported approval of ATX-101 in the United
States and Canada, are reported.
METHODS
Study design
REFINE-2 (NCT01546142) was a randomized,
double-blind, placebo-controlled trial conducted at
35 sites in the United States and Canada between
March 2012 and August 2013 in accordance with
International Conference on Harmonisation
Tripartite Guidelines on Good Clinical Practice
and applicable Food and Drug Administration
regulations. Central and local institutional review
boards approved the protocol. All patients provided
written informed consent. Financial compensation
of patients was at the discretion of each study site.
Patients were randomized 1:1 to receive ATX-101
(dose strength: 2 mg/cm2) or placebo (phosphate-
buffered saline preserved with 0.9% benzyl alcohol)
via subcutaneous injections into preplatysmal fat
(Supplementary Fig 1). Patients received 10 mL or
less (#100 mg) of study drug per treatmentadministered in 0.2-mL injec-
tions with a 30-gauge, 0.5-in
needle attached to a 1-mL
syringe at 1.0-cm spacing us-
ing a grid. Up to 6 treatments
(28 6 5 days apart) were
permitted, but fewer were
allowed because of efficacy
(insufficient SMF to inject,
patient satisfaction with
treatment), safety/tolerability
concerns, or administrative
reasons. Ice or topical/local
anesthetics could be applied
to the treatment area at the
investigator’s discretion.
Before patient recruitment,investigators attended injection training and were
required to view an injection training video.
Patients
Adults aged 18 to 65 years who were dissatisfied
with the appearance of their face/chin (rating of 0, 1,
or 2 on Subject Self-Rating Scale; details of all scales
summarized in Table I) and whose SMF was rated as
moderate (grade 2) or severe/large (grade 3) on both
the validated Clinician- and Patient-Reported SMF
Rating Scales were eligible. Body weight had to be
stable for at least 6 months based on investigator
judgment. Key exclusion criteria were body mass
index higher than 40 kg/m2; excessive submental
skin laxity based on investigator judgment; and
prior intervention(s) to treat SMF, including
radiofrequency, lasers, chemical peels, or dermal
fillers in neck/chin within 12 months, botulinum
toxin injections in neck/chin within 6 months, or
history of liposuction, surgery, or treatment with
lipolytic agents. In addition, for centers selected to
conduct magnetic resonance imaging (MRI), any
patient with a condition that would render him or
her unsuitable for MRI was excluded. Full exclusion
criteria are listed in Supplementary Table I.
End points
Coprimary end points, evaluated at 12 weeks after
last treatment, were proportion of patients who
achieved improvement of 1 or more grades on
both the Clinician- and Patient-Reported SMF
Abbreviations used:
AE: adverse event
MMN: marginal mandibular nerve
MRI: magnetic resonance imaging
PR-SMFIS: Patient-Reported Submental Fat
Impact Scale
SMF: submental fat
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achieved improvement of 2 or more grades on
both scales.
The first of 2 secondary end points was
proportion of patients who achieved a 10% or
more reduction from baseline in MRI-measured
submental volume (defined a priori as a responder),
which was evaluated in a subset of patients (MRI
methodology reported previously8). The other
secondary end point was change from baseline in
psychological impact of SMF using the Total Scale
Score from the validated Patient-Reported SMF
Impact Scale (PR-SMFIS).
Additional end points included change from base-
line in SMF thickness using calipers; change from
baseline in PR-SMFIS component scores; proportion
of patients who achieved improvement of 1 or more
grades or 2 or more grades independently on the
Clinician- and Patient-Reported SMF Rating Scales;
proportion of patients satisfied with the appearance
of their face/chin (based on Subject Self-Rating Scale);
proportion of patients satisfied with the fat under their
chin, definition between their chin and neck, and with
treatment (based on Subject Global Questions 1-3,
respectively); and assessment of SMF based on stan-
dardized linedrawingsof submental convexity.All end
points were evaluated at 12 and 24 weeks after last
treatmentwith theexception of submental volume (via
MRI) and Subject Global Questions, which were only
evaluated at 12 weeks after last treatment. For docu-
mentation, standardized photography was performed
at screeningand at 12and24weeks after last treatment.
Safety was evaluated throughout the trial via
visual and tactile assessment of the submental area,
spontaneous reports of adverse events (AEs), clinical
laboratory tests, vital signs, body weight, and
physical examinations. Submental skin laxity was
graded by the investigator using the Submental Skin
Laxity Grade scale.
Statistical analysis
A sample of 250 patients per treatment group
provided 92.8% power to detect differences on the
2 coprimary end points (composite $1-grade and
$2-grade responder rate), and 99.9% power for the
secondary end point of change from baseline inPR-SMFIS Total Scale Score. A sample of 100 patients
per treatment group provided 99.9% power for the
secondary end point of MRI-based submental
volume responder rate. Power calculations assumed
a 10% dropout, 2-tailed tests, a = 0.05 for the
coprimary end points, and multiplicity-adjusted
a = 0.025 for the 2 secondary end points, and were
based on responder rates observed in an earlier
ATX-101 trial (NCT01032889). MRIs were performed
at 16 centers (identified before trial start); the first
approximately 200 patients randomized at these
centers underwent MRI.
Formal hypotheses tests were conducted for the
coprimary end points (a = 0.05), and for the 2
secondary end points (using a Bonferroni-Holm
adjustment for 2 tests), in the intent-to-treat
population, with multiple imputation of missing
data. A Cochran-Mantel-Haenszel analysis stratified
by site was performed for responder end points.
Sensitivity analyses assessed the impact of the
method of imputation and method of statistical
analysis on the primary end point analyses.
Continuous variables were analyzed using an
analysis of covariance model with treatment as fixed
effect and baseline value as covariate. All statistical
analyses were performed using SAS, Version 9.2 or
higher (SAS Institute, Cary, NC).
RESULTS
Patient disposition and baseline
characteristics
Overall, 516 patients were randomized (ATX-101,
258; placebo, 258) (Supplementary Fig 2).
Demographic and baseline characteristics are shown
in Table II. Across both groups, 86.0%of patientswere
white, 86.2% were female, mean age was 47.9 years
(SD 9.1), and mean body mass index was 29.3 kg/m2
(4.5). All Fitzpatrick skin types were represented.
Treatment characteristics
The total mean volume (SD) of study drug
injected across all treatments was 25.6 (14.6) mL in
the ATX-101 group and 32.3 (15.1) mL in the placebo
group. Injected volume decreased by 28% and 17%
for ATX-101 and placebo patients, respectively, over
successive treatments. Overall, 119 of 258 (46.1%)
patients treated with ATX-101 received fewer than
6 treatments, with 56 of 119 (47.1%) stopping
treatment because of efficacy and 17 of 119 (14.3%)
because of AEs (Supplementary Fig 2).
Efficacy
At 12 weeks after last treatment, more patients
treated with ATX-101 (66.5%) than placebo (22.2%)
achieved a composite improvement of 1 or more
Table II. Demographic and baseline characteristics
Placebo, n = 258 ATX-101, n = 258
Age, mean (SD), y 47.6 (9.0) 48.2 (9.3)
Female, n (%) 224 (86.8) 221 (85.7)
Race, n (%)
White 222 (86.0) 222 (86.0)
Black 21 (8.1) 24 (9.3)
Asian 5 (1.9) 4 (1.6)
Other 10 (3.9) 8 (3.1)
Hispanic or Latino, n (%) 39 (15.1) 40 (15.5)
Weight, mean (SD), kg 80.3 (15.0) 81.4 (14.8)
BMI, mean (SD), kg/m2 29.3 (4.3) 29.2 (4.8)
SMF grade as assessed by CR-SMFRS/PR-SMFRS, n (%)
Grade 2 131 (50.8)/160 (62.0) 126 (48.8)/162 (62.8)
Grade 3 126 (48.8)/97 (37.6) 131 (50.8)/95 (36.8)
Missing 1 (0.4)/1 (0.4) 1 (0.4)/1 (0.4)
Fitzpatrick skin type, n (%)
I-III 176 (68.2) 170 (65.9)
IV-VI 82 (31.8) 88 (34.1)
Intent-to-treat population.
BMI, Body mass index; CR-SMFRS, Clinician-Reported Submental Fat Rating Scale; PR-SMFRS, Patient-Reported Submental Fat Rating Scale;
SMF, submental fat.
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confidence interval [CI] 2.31-3.85; P\.001). A greater
proportion of those treated with ATX-101 than
placebo also achieved the more stringent composite
improvement in SMF of 2 or more grades (ATX-101,
18.6%; placebo, 3.0%; Mantel-Haenszel risk ratio
6.27; 95% CI 2.91-13.52; P \ .001). Furthermore,
both primary end points were met in all sensitivity
analyses, indicating the results were robust (P\.001
for all). Representative photographs of patients with
improvement of 1 ormore grades (Fig 1,A andB) and
2 or more grades (Fig 1, C ) demonstrate clinical
outcomes with ATX-101.
MRI analyses, conducted in 225 patients,
showed that a greater proportion of patients
treated with ATX-101 versus placebo achieved a 10%
or more reduction in submental volume (40.2%
vs 5.2%, respectively; Mantel-Haenszel risk ratio
7.84; 95% CI 3.30-18.62; P \ .001) (representative
examples in Fig 1, A and B). The reduction in
submental volume was greater with ATX-101 versus
placebo treatment (P\ .001) (Table III). In addition,
thepercentage reduction inSMF thicknessasmeasured
by calipers was greater with ATX-101 versus placebo
(P\.001) (Table III).
At baseline, patients in both treatment groups
reported psychological impact from their SMF
(Fig 2). The reduction in PR-SMFIS Total Scale Score
was significantly greater for patients receiving
ATX-101 than placebo (P \ .001) (Fig 2). Similar
significant differences were observed for the
individual PR-SMFIS components (P \ .001 for all)
(Fig 2). In addition, a greater proportion of patientstreated with ATX-101 indicated satisfaction with the
appearance of their face/chin after treatment versus
patients treated with placebo (P\ .001) (Table III).
Additional efficacy results are summarized inTable III.Safety
Table IV reports the proportion of patients who
experienced AEs during the trial. Most AEs were
localized to the injection site: 85.7% in the ATX-101
group and 76.9% in the placebo group. Most AEs
resolved within 14 days (67.3% in the ATX-101 group
and 83.5% in the placebo group) and nearly all
resolved by study end (96.8% and 96.6%,
respectively). Injection-site AEs reported in 5% or
more of patients are listed in Table IV. Fig 3 shows the
incidence and severity of injection-site swelling/
edema, bruising, and pain over the 6 treatments.
Median durations of most injection-site AEs ranged
from3.0 to 15.5 days in theATX-101 group, except for
nodule (20.0 days), induration (26.4 days), and
anesthesia (33.0 days). In the placebo group, median
durations ranged from 2.0 to 8.7 days. Serious AEs
were uncommon and none were related to study
drug. One patient in the ATX-101 group died in a
motor vehicle accident and 1 patient in the placebo
group died from heroin toxicity; neither death
was related to study drug. Results of physical
examinations, vital signs, and laboratory tests did
not suggest a safety signal. Submental skin laxity was
unchanged or improved from baseline in 94.1% of
those treated with ATX-101 and 94.8% of those
treated with placebo.
Fig 1. A, Standardized photographs and magnetic resonance imaging (MRI) of a 51-year-old
man who underwent 6 treatment sessions with ATX-101 and achieved a composite
improvement of 1 or more grades (Clinician-Reported Submental Fat Rating Scale
[CR-SMFRS]/Patient-Reported Submental Fat Rating Scale [PR-SMFRS]) at 12 weeks after
last treatment. Percentage reduction in submental volume as assessed by MRI was 14%.
B, Standardized photographs and MRI of a 56-year-old woman who underwent 5 treatment
sessions with ATX-101 and achieved a composite improvement of 1 or more grades
(CR-SMFRS/PR-SMFRS) at 12 weeks after last treatment. Percentage reduction in submental
volume as assessed by MRI was 2%. C, Standardized photographs of a 43-year-old woman who
underwent 4 treatment sessions with ATX-101 and achieved a composite improvement of 2 or
more grades (CR-SMFRS/PR-SMFRS) at 12 weeks after last treatment. BMI, Body mass index;
PR-SMFIS, Patient-Reported Submental Fat Impact Scale; SMSLG, Submental Skin Laxity Grade;
SSRS, Subject Self-Rating Scale.
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occurred in 11 (4.3%) of those treated with
ATX-101 and 2 (0.8%) treated with placebo
corresponding to a relative session frequency of
0.9% and 0.1%, respectively. Most events of MMN
paresis were mild or moderate and all were
temporary and resolved without sequelae. One
severe event occurred in a patient treated with
ATX-101 (resolved within 85 days); this patient
went on to receive additional treatment, was a
responder, and was satisfied. Median durations of
mild MMN paresis events were 41.0 (range 7.0-60.0)
days in the ATX-101 group (n = 8) and 54.0 days in
the placebo group (n = 1). Similarly, for moderate
MMN paresis events, median durations were
56.5 (range 52.0-61.0) days (n = 2) and 115.0 days
(n = 1), respectively. One event of mild superficial
skin ulceration occurred in a patient treated withATX-101 (on the day of the sixth treatment) and
resolved within 23 days. Dysphagia associated with
the volume of injection or postinjection swelling/
pain occurred in 6 (2.3%) of those treated with
ATX-101 and 1 treated with placebo (0.4%). Median
durations of dysphagia were 2.5 days in the ATX-101
group and 1.0 day in the placebo group and resolved
without sequelae.
DISCUSSION
REFINE-2 evaluated the efficacy and safety of
ATX-101, a first-in-class injectable drug for SMF
reduction. Both coprimary end points were met
with a high degree of statistical significance, and all
secondary and additional end points significantly
favored ATX-101, demonstrating its efficacy for
reducing SMF. MRI supported substantial reduction
in submental volume after ATX-101 treatment. In
Fig 1. (continued).
Fig 1. (continued).
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clinically meaningful reduction in psychological
impact of their SMF; they were happier, less
bothered, less self-conscious, and less embarrassed
about their SMF and looked younger and less
overweight after ATX-101 treatment. Overall, agree-
ment among investigator-reported, patient-reported,
and objective assessments of the submental area
strongly suggests that the aesthetic improvement
after ATX-101 treatment was clinically meaningful,and the objective tool-based measures showed that
there was little SMF reduction in the placebo group
relative to the ATX-101 group. Moreover, the results
were similar to those of REFINE-1,8 which used an
identical protocol with different investigators,
illustrating the consistent effect with ATX-101
treatment.
The safety profile of ATX-101 is consistent with
the injection procedure and its mechanism of action.
Most AEs were localized to the injection site,
Table III. Secondary and additional efficacy end points evaluated at 12 weeks after last treatment
Intent-to-treat MRI population Placebo, n = 112 ATX-101, n = 113
MRI responder,* n (%) 6 (5.2) 45 (40.2)
Submental volume, LSM (SE) percentage change from baseline 1.1 (0.9) 8.6 (0.9)
Intent-to-treat population Placebo, n = 258 ATX-101, n = 258
CR-SMFRS $1-grade improvement, n (%) 89 (34.5) 201 (77.9)
PR-SMFRS $1-grade improvement, n (%) 97 (37.8) 202 (78.4)
CR-SMFRS $2-grade improvement, n (%) 26 (9.9) 100 (38.7)
PR-SMFRS $2-grade improvement, n (%) 20 (7.9) 80 (30.8)
Caliper measurements of SMF thickness, LS mean (SE) percentage
change from baseline
8.4 (1.3) 17.8 (1.3)
SSRS responder,y n (%) 83 (36.2) 163 (75.1)
SGQ responder,z n (%)
1 (Fat under chin) 56 (24.7) 152 (70.7)
2 (Definition between chin and neck) 49 (21.6) 145 (67.4)
3 (Satisfied with treatment) 77 (33.9) 162 (75.3)
Patient line drawing assessment, LSM (SE) change from baseline 0.4 (0.1) 1.2 (0.1)
P\ .001 for all comparisons between ATX-101 and placebo.
CR-SMFRS, Clinician-Reported Submental Fat Rating Scale; LSM, least squares mean; MRI, magnetic resonance imaging; PR-SMFRS,
Patient-Reported Submental Fat Rating Scale; SGQ, Subject Global Question; SMF, submental fat; SSRS, Subject Self-Rating Scale.
*Defined a priori as achieving $10% reduction from baseline in submental volume via MRI.
yResponse was slightly satisfied, satisfied, or extremely satisfied.
zResponse was 1 of the 2 highest positive categories (ie, moderately better or a great deal better; moderately satisfied or extremely
satisfied).
Fig 2. Mean change from baseline in the Total Scale Score and individual component scores of
the Patient-Reported Submental Fat Impact Scale (PR-SMFIS ) at 12 weeks after last treatment.
P\ .001 for all comparisons between ATX-101 and placebo. Tx, Treatment.
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794 Humphrey et almild/moderate, transient, did not prevent continued
treatment, and decreased in incidence over
subsequent treatments. Implementation of addi-
tional comfort measures (eg, injected lidocaine,
nonsteroidal anti-inflammatory drugs) may reduce
the incidence and severity of common treatment area
reactions, such as swelling, bruising, and pain.Although instances of MMN paresis were primarily
mild and always temporary, these observations
emphasize the importance of physician training
and education regarding anatomy of the submental
area before ATX-101 administration. The anatomical
course of the MMN is variable and runs both inferior
and superior to the mandibular border.13 Posterior to
Table IV. Summary of adverse events (safety
population)
AE, n (%)
Placebo,
n = 256
ATX-101,
n = 258
AEs 236 (92.2) 252 (97.7)
Mild* 141 (55.1) 100 (38.8)
Moderatey 92 (35.9) 120 (46.5)
Severez 3 (1.2) 32 (12.4)
Seriousx 10 (3.9)* 7 (2.7)y
Injection-site AEs reported in $5% of patients in either
treatment group
Pain 100 (39.1) 190 (73.6)
Hematoma (bruising) 186 (72.7) 188 (72.9)
Edema 93 (36.3) 175 (67.8)
Anesthesia (numbness) 18 (7.0) 169 (65.5)
Erythema 65 (25.4) 91 (35.3)
Swelling 40 (15.6) 75 (29.1)
Induration 9 (3.5) 73 (28.3)
Pruritus 21 (8.2) 42 (16.3)
Paresthesia 11 (4.3) 38 (14.7)
Nodule 11 (4.3) 37 (14.3)
Skin tightness 5 (2.0) 19 (7.4)
Noninjection-site AEs reported in $5% of patients in either
treatment group
Headache 8 (3.1) 23 (8.9)
Upper respiratory tract infection 18 (7.0) 15 (5.8)
Nasopharyngitis 13 (5.1) 12 (4.7)
AE, Adverse event.
*Patient is aware of a sign or symptom but it is easily tolerated.
yDiscomfort or interference with usual activity.
zIncapacitating with inability to engage in usual activity.
xAn event that may constitute a significant medical hazard or side
effect regardless of relationship to the study drug, including but
not limited to it: is fatal, is life-threatening, requires hospitalization
or prolongs hospitalization, results in persistent or significant
disability/incapacity, and is a congenital anomaly/birth defect.
Serious AEs in the placebo group were: acute congestive heart
failure (n = 1), pancreatitis (n = 1), vaginal repair (n = 1), transient
ischemic attack (n = 1), breast cancer (n = 1), heroin toxicity
(n = 1), diverticulitis (n = 1), influenza (n = 1), spinal cord infection
(n = 1), hip surgery (n = 1). Serious AEs in the ATX-101 group were:
ovarian cancer/uterine cancer (n = 1), uterine prolapse/cystocele/
rectocele/uterine leiomyoma (n = 1), gastroesophageal reflux
disease (n = 1), intervertebral disc operation (n = 1), motor
vehicle accident (n = 1), recurrent breast cancer (n = 1), urinary
tract infection (n = 1).
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to the mandible. Anterior to this bony landmark
(at the anterior portion of the masseter muscle),
the MMN courses superficially over the mandible to
innervate the lip depressors.14 To prevent MMN
injury, it is recommended to avoid injecting
ATX-101 above a line drawn 1.0 to 1.5 cm below
the inferior mandibular border.5 One instance of skin
ulceration occurred, underscoring the importance of
injecting ATX-101 midway into the SMF to avoid the
dermis.Submental skin laxity was unchanged or
improved in the large majority of patients in
REFINE-2, which is remarkable because MRI and
caliper assessments showed significant reductions in
submental volume and SMF thickness in those
treated with ATX-101. All things being equal, one
might expect a worsening of skin laxity after SMF
reduction without concomitant skin retraction.
Evidence of neocollagenesis and thickening of
fibrous septae have been observed after ATX-101
treatment6 and may contribute to skin retraction
despite submental volume reduction observed
across phase III ATX-101 trials.7,8,10
In REFINE-2, follow-up was limited to 44 weeks
(24 weeks after last treatment), which limits
conclusions regarding the long-term durability of
ATX-101 treatment. However, a durable response is
expected once the aesthetic goal is achieved because
ATX-101 destroys adipocytes and creates fibrosis.6
Follow-up of patients from phase II/III trials has
demonstrated that improvements in submental
contour achieved with ATX-101 are maintained
over time in most patients (current data supporting
maintenance of effect for up to 4 years).15 Based on
results from the REFINE trials, ATX-101 was
approved in the United States and Canada for adults
with moderate to severe SMF. Studies to evaluate
ATX-101 in additional populations, such as patients
with mild or extreme SMF and patients older than
65 years, are underway. In addition, CONTOUR
(Condition of Submental Fullness and Treatment
Outcomes Registry) is evaluating the management
of submental fullness in clinical practice and will
provide real-world data on ATX-101.
In summary, the results from REFINE-2 are
clinically meaningful, statistically significant, and
consistent with efficacy and safety outcomes
observed in other phase III ATX-101 trials.7,8,10 The
current findings further support ATX-101 as a
minimally invasive alternative to aesthetic surgical
procedures and liposuction for SMF reduction.
We thank the investigators from the REFINE-2 trial:
Jeffrey Adelglass, Lorne Albrecht, Sarah Arron, Diane
Baker, Stephen Baker, Lawrence Bass, Ashish C. Bhatia,
Fredric S. Brandt, Joel Cohen, Steven Davis, Steven H.
Dayan, Jeanine Downie, Zoe Draelos, Robert Fixler, Peter
Fodor, Holly Hake-Harris, William Hanke, Michael Jarratt,
Bruce Katz, Rebecca Kazin, Corey Maas, Ronald Moy,
Rhoda Narins, Gary Petrus, Sheetal Sapra, Ava Shamban,
Daniel Stewart, Derek Woolner, Douglas Woseth, Leroy
Young, and Brian Zelickson. Magnetic resonance imaging
was interpreted in a blinded manner by Vahan Sharoyan,
PhD, and Miki Sode, PhD, of BioClinica Inc (formerly
SYNARC Inc), Newark, CA.
Fig 3. Incidence, severity, and duration of injection-site adverse events (AE ) (swelling/edema,
bruising, and pain) for individual treatment sessions. At the top of the graph, the number of
patients reporting the AE is listed in the first row; the total number of patients is listed in the
second row. The number listed at the top of each bar is the median duration of the AE in a
particular session. For session frequency, the data for the percentage of sessions for which the
AE was reported are shown. A, ATX-101; P, placebo.
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Table I. Scales used in the REFINE-2 trial
Scale Description
CR-SMFRS* d Submental convexity evaluated by the clinician on a 5-point ordinal scale with:
B 0 = absent
B 1 = mild
B 2 = moderate
B 3 = severe
B 4 = extreme
d Photonumeric guide included to assist clinicians in applying the ratings (Supplementary Fig 3)
PR-SMFRS* d SMF evaluated by the patient on a 5-point ordinal scale with:
B 0 = no chin fat at all
B 1 = a slight amount of chin fat
B 2 = a moderate amount of chin fat
B 3 = a large amount of chin fat
B 4 = a very large amount of chin fat
PR-SMFIS* d Psychological impact of SMF on self-perception of 6 emotional and visual characteristics related
to the appearance of submental fullness assessed with the following items:
B How happy are you with the appearance of your chin fat?
B How bothered are you by the appearance of your chin fat?
B How self-conscious are you about the appearance of your chin fat?
B How embarrassed are you about the appearance of your chin fat?
B How much older do you look because of your chin fat?
B How much overweight do you look because of your chin fat?
d Each item rated on an 11-point numeric scale (0-10)
B Scores for the 6 items were combined to generate a PR-SMFIS Total Scale Score
B Lower scores indicate improvement or reduced negative impact of these items
SSRS d Overall satisfaction with the appearance of the face and chin evaluated by the patient on
a 7-point scale with:
B 0 = extremely dissatisfied
B 1 = dissatisfied
B 2 = slightly dissatisfied
B 3 = neither satisfied nor dissatisfied
B 4 = slightly satisfied
B 5 = satisfied
B 6 = extremely satisfied
d A responder was a patient whose response was 4, 5, or 6
SGQ d Fat under chin (SGQ no. 1) and definition between chin and neck (SGQ no. 2) compared with
how they were before treatment, and satisfaction with treatment (SGQ no. 3) evaluated by the
patient
d Response options for SGQ nos. 1 and 2:
B A great deal worse
B Moderately worse
B A little worse
B About the same
B A little better
B Moderately better
B A great deal better
d Response options for SGQ no. 3:
B Extremely dissatisfied
B Moderately dissatisfied
B A little dissatisfied
B Neither dissatisfied or satisfied
B A little satisfied
B Moderately satisfied
B Extremely satisfied
d A responder was a patient whose response was 1 of the 2 highest positive categories
Continued
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Table I. Cont’d
Scale Description
SMSLG d Skin laxity assessed by the clinician as an integration of 3 features: skin wrinkling, adherence to
underlying neck structures (bone and muscle), and redundancy (horizontal and vertical folds)
on a 4-point scale with:
B 1 = none
B 2 = mild
B 3 = moderate
B 4 = severe
d Each grade (none, mild, moderate, and severe) defines the maximal allowed limit for skin
wrinkling, adherence to underlying structures, and redundancy. The feature with the highest grade
determines the SMSLG
d Photonumeric guide included to assist clinicians in applying the ratings (Supplementary Fig 4)
Standardized line
drawings of
submental
convexity
d From 10 line drawings that included 2 examples representing each of the 5 CR-SMFRS scores,
provided to the patient in a shuffled order, patients were asked to select the drawing that best
represented their profile
d Assessments scored from 0 to 4, where 0 = lowest SMF score and 4 = highest SMF score,
such that a lower score was better
CR-SMFRS, Clinician-Reported Submental Fat Rating Scale; PR-SMFIS, Patient-Reported Submental Fat Impact Scale; PR-SMFRS,
Patient-Reported Submental Fat Rating Scale; SGQ, Subject Global Question; SMF, submental fat; SMSLG, Submental Skin Laxity Grade;
SSRS, Subject Self-Rating Scale.
*Validated scale.
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Supplementary Fig 1. Study design. aPosttreatment, relative to the patient’s last treatment
session, irrespective of when that occurred. Analyses were made after the last patient
completed visit 9 (week 32; 12 weeks after last treatment). MRI, Magnetic resonance imaging.
J AM ACAD DERMATOL
OCTOBER 2016
797.e3 Humphrey et al
Supplementary Fig 2. Patient disposition. The intent-to-treat population included all
randomized patients and was used to evaluate efficacy. Magnetic resonance imaging (MRI )
assessments were conducted on a subgroup of the intent-to-treat population. The safety
population included all randomized patients who received 1 or more injections of study drug
and was used to evaluate safety. SMF, Submental fat.
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Supplementary Fig 3. Photonumeric guide for assessment of submental fat (SMF) using the
Clinician-Reported Submental Fat Rating Scale. Adapted fromMcDiarmid J, Ruiz JB, Lee D, et al.
Results from a pooled analysis of two European, randomized, placebo-controlled, phase 3
studies of ATX-101 for the pharmacologic reduction of excess submental fat. Aesthetic Plast
Surg. 2014;38:849-60.9
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Supplementary Fig 4. Photonumeric guide for assessment of skin laxity using the Submental
Skin Laxity Grade scale. Reproduced with permission from Jones DH, Carruthers J, Joseph JH,
et al. REFINE-1, a multicenter, randomized, double-blind, placebo-controlled, phase 3 trial with
ATX-101, an injectable drug for submental fat reduction. Dermatol Surg. 2016;42:38-49.8
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Supplementary Table I. Full list of exclusion criteria
n History of any intervention to treat SMF (eg, liposuction, surgery, lipolytic agents)
n History of trauma associated with the chin/neck area
n A grade of 4 on the Submental Skin Laxity Grade or other anatomical feature (eg, predominant postplatysmal fat, loose
skin in the neck/chin area, prominent platysmal bands), as assessed within 28 d before randomization, for which reduction
in SMF may, in the judgment of the investigator, result in an aesthetically unacceptable outcome
n Evidence of any cause of enlargement in the submental area (eg, thyroid enlargement, cervical adenopathy) other than
localized SMF
n BMI[40 kg/m2
n History or current symptoms of dysphagia
n A result on coagulation tests (prothrombin time, partial thromboplastin time) obtained within 28 d before randomization
indicating the presence of any clinically significant bleeding disorder
n Any medical condition (eg, respiratory, cardiovascular, hepatic, neurologic disease, thyroid dysfunction) that would
interfere with assessment of safety or efficacy or compromise the patient’s ability to undergo study procedures or give
informed consent
n Treatment with radiofrequency, laser procedures, chemical peels, or dermal fillers in the neck/chin area within 12 mo
before randomization
n Treatment with botulinum toxin injections in the neck/chin area within 6 mo before randomization
n History of sensitivity to any components of the study drug
n History of sensitivity to topical or local anesthetics (eg, lidocaine, benzocaine, procaine)
n Previous randomization in this study or previous participation in a Kythera Biopharmaceuticals, Incesponsored ATX-101
study
n Treatment with an investigational device or agent within 30 d before randomization
BMI, Body mass index; SMF, submental fat.
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